Oral Drug Delivery Videos

  1. Patient- And Planet-Centric Bioavailability And Sustained Delivery

    By reducing the size of drug particles, nanoforming offers new opportunities — from increased bioavailability to sustained drug delivery. Discover the potential benefits supported by case studies.

  2. Understanding The Global Regulatory Landscape For Combination Products 8/14/2025

    In this videocast episode, host Tom von Gunden discusses Chapter 14 of The Combination Products Handbook (CRC Press) with the book’s editor Susan Neadle, along with chapter coauthors Stephanie Goebel, Cherry Malonzo Marty, and Viky Verna. The group provides overviews of the commonalities and variances in regulatory definitions and guidances for combination products across global jurisdictions and agencies. 

  3. Taste Masking 101: Applications And Technologies 9/28/2021

    Learn about key product parameters affecting patient acceptability and therapy adherence and taste masking strategies, including organoleptic and barrier coating approaches and microencapsulation technologies.

  4. When And How To Use A UFMEA During Device Design 12/11/2024

    When and how might using a uFMEA (Use Failure Mode Effects Analysis) tool benefit biopharma companies addressing regulatory expectations for analyses of risk and/or human factors? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, and Shannon Hoste, chief scientific officer at Pathway for Patient Health, discuss potential differences in the contexts, purposes, and degrees of detail in information presented for review.

  5. Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load 8/13/2024

    Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

  6. What Types Of Products Are Assessed With A URRA? 12/11/2024

    What types of products in development may need to be assessed in accordance with the FDA’s URRA (Use-Related Risk Analysis) guidance? In this segment of the Drug Delivery Leader Live event Human Factors Risk Analysis: Leveraging URRA And UFMEA Tools, Natalie, Abts, head of human factors engineering at Genentech, describes several common scenarios that illustrate when a URRA approach may or may not be needed.

  7. Understanding How EDDOs Relate To CGMPs 4/23/2025

    How are EDDOs (Essential Drug Delivery Outputs) related to CGMPs (Current Good Manufacturing Practices) during the design of a drug-led or biologic-led combination product? In this segment of the Drug Delivery Leader Live event EDDOs Revisited: Putting Essential Drug Delivery Outputs Into Practice, consultant Susan Neadle of Combination Products Consulting Services, LLC establishes the connection between the two regulatory concepts.

  8. Solid Form Screening Of Active Pharmaceutical Ingredients

    Explore the role of solid form services in helping meet accelerated timelines of the drug development lifecycle along with examples of robust workflows for fast and thorough solid form screens.

  9. Post-Market Surveillance And Post-Approval Changes For Combination Products 1/12/2026

    In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on post-market regulatory considerations and processes for combination products. Among the topics covered are post-approval changes, design outputs, patient safety, and various regulatory guidances.

  10. Orally Administered Botanical Therapies Targeting ASD With DeFloria's Jared And Joel Stanley 5/19/2025

    In this episode of Sit and Deliver, host Tom von Gunden talks with Jared Stanley, CEO, and Joel Stanley, board chairman, from DeFloria, a botanical therapeutics development company. Tom talks with the Stanley brothers about cannabinoid-based therapies targeting Autism Spectrum Disorder (ASD). The discussion covers aspects of drug development and delivery including molecule characterization, formulation, and dosing for oral administration, as well as key considerations for commercial-scale production and distribution of regulated botanicals.